目的 系统解析抗体药物偶联物（ADCs）在泛肿瘤治疗领域的研究态势、合作网络与热点，为该领域的科研布局及发展提供参考。方法 基于Web of Science核心合集，检索2015年1月1日—2025年8月20日期间ADCs在泛肿瘤治疗方面的相关文献，运用VOSviewer与CiteSpace工具，从年度发文、作者、机构、国家、期刊、高被引文献及关键词等维度进行文献计量与可视化分析。结果 共纳入文献3 192篇，本领域年度发文量呈指数级增长，至2024年已达到607篇的峰值。合作网络分析显示已形成以Curigliano Giuseppe等学者为核心的国际性研究团队。在机构层面，哈佛医学院以34篇的发文量位居首位，同时呈现出学术界、顶尖医疗机构（如哈佛大学、Dana-Farber癌症研究所）与制药企业（如Genentech）深度融合的协作模式。国家分析表明，美国与中国共同构成了该领域的双核心领导力量，欧洲则作为重要的次研究中心。核心期刊分布覆盖肿瘤学、药物研发及基础研究等多个方向，凸显出研究的交叉学科特征。关键词与高被引文献分析揭示，该领域研究脉络经历了从基础探索、临床验证到创新拓展3大阶段。当前研究前沿主要集中于德曲妥珠单抗（T-DXd）、戈沙妥珠单抗（SG）等新一代ADCs药物，并进一步深入至克服耐药性、探索与免疫检查点抑制剂的联合疗法，以及开发TROP-2等新型靶点的ADCs药物。结论 ADCs在泛肿瘤领域正处于高速发展期，呈现全球化、跨学科、产学研紧密结合的特征。研究焦点已成功从早期技术构建过渡至以关键药物和适应证为核心的临床转化阶段，并正向克服耐药、优化设计及联合治疗等深层次科学问题迈进。

Objective To systematically analyze the research trends, collaboration networks, and development hotspots of antibodydrug conjugates (ADCs) in the field of pan-tumor treatment, and to provide references for scientific research planning and future development in this field. Methods Based on the Web of Science Core Collection, relevant literature on ADCs in cancer treatment from January 1, 2015 to August 20, 2025 was retrieved. Bibliometric and visual analyses were conducted using VOSviewer and CiteSpace tools, examining dimensions such as annual publication output, authors, institutions, countries, journals, highly cited literature, and keywords. Results A total of 3 192 articles were included and the annual number of publications on ADCs increased markedly, reaching a peak of 607 articles in 2024, with research activity continuing to grow steadily. In terms of collaboration, an international author team was established with Curigliano G. et al. at its core, while Harvard Medical School contributed the highest number of publications (34). The overall collaboration network demonstrates a strong integration among academic institutions, medical centers, and pharmaceutical companies—such as Harvard University, Dana-Farber Cancer Institute, and Genentech. At the country level, the United States and China formed a dual core, while European countries acted as a secondary hub. Core journals spanned the fields of oncology, drug development, and basic research, underscoring the highly interdisciplinary nature of ADC studies. Analysis of highly cited literature and keyword evolution indicated that the field progressed through three main phases: basic exploration, clinical validation, and innovation/expansion. Next-generation agents such as trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) became research foci. Current hotspots include overcoming drug resistance, exploring combination therapies with immune checkpoint inhibitors, and developing novel targets such as TROP-2. Conclusion This study indicates that ADC research is experiencing a period of rapid advancement, marked by global collaboration, interdisciplinary integration, and strong ties between industry and academia. The research emphasis has shifted from early technology development to clinical application driven by key drugs and indications, and is now moving toward addressing more complex challenges including drug resistance, optimization of molecular design, and rational combination strategies.

R979.1

漯河市科技创新团队项目；河南省科技攻关项目（252102310430，252102310312）；河南省自然科学基金项目（252300423172，252300420627）；北京科技创新医疗发展基金会肿瘤研究基金（KC2023-JX-0186-RQ065）；2022年河南省中央引导地方科技发展资金项目（Z20221343023）；漯河医学专科学校创新创业能力提升工程团队项目（2021LYZTDXM012）